CHMP recommends Novo Nordisk's Saxenda for adolescents
The EU Committee for Medicinal Products for Human Use (CHMP) which recommends drugs for approval in Europe, vouches for an expanded indication of Novo Nordisk's obesity drug Saxenda, so it can be used for adolescents aged 12-17 years.
BY RITZAU, TRANSLATED BY NIELSINE NIELSEN
European health authorities recommend an extended use of Novo Nordisk's weight loss drug Saxenda so that it may also be used for treating obesity in children and adolescents aged 12-17, according to a Novo Nordisk press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA refuses to file Novo Nordisk application
For subscribers
.jpg&w=384&q=75)
